Diligence memo · auto-generated · as of July 3, 2026
Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. has raised $303M over 3 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Nautilus Biotechnology, Inc. operates in Biotech, based in San Carlos.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nautilus Biotechnology, Inc. has raised $303M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $200M on 2021-06-09.
Most recent recorded round closed around 2021-06-09.
Valuation (modeled)modeled
Provath models Nautilus Biotechnology, Inc. at approximately $6.0B (range $907M–$11.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 5.1 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotech peers (233 compared).
Modeled value ranks above 100% of those peers.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.